Physician profile
Thomas Mastri
NPI 1073566642
$3,883.83
in general payments reported to CMS, 2019-2025
30 companies · $528 in 2025
The $528 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $289 · 2021: $880 · 2022: $777 · 2023: $585 · 2024: $568 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615 · Education: $65.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,614.83 |
| Education | $65.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,389.32 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $531.64 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $436.24 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $162.46 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.12 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $149.06 | 2019-2024 | |
| Celltrion USA INC. | $125.92 | 2024-2025 | Vegzelma, Zymfentra |
| Celgene Corporation | $89.75 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $77.90 | 2022-2023 | Ocaliva |
| Ardelyx, INC. | $75.36 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $62.29 | 2021 | |
| Merck Sharp & Dohme LLC | $60.58 | 2021-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $59.43 | 2020 | |
| Qol Medical, LLC | $58.24 | 2021-2025 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $50.09 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $46.67 | 2024 | Iqirvo, Bylvay |
| Allergan, INC. | $40.40 | 2019-2020 | |
| Boston Scientific Corporation | $36.62 | 2024 | Watchman Access System |
| Covidien LP | $34.53 | 2019 | |
| Madrigal Pharmaceuticals | $32.48 | 2025 | Rezdiffra |
| Amgen INC. | $29.12 | 2022 | |
| Evoke Pharma, INC. | $27.50 | 2023-2024 | Gimoti |
| Phathom Pharmaceuticals, INC. | $24.91 | 2025 | Voquezna |
| Novo Nordisk INC | $22.79 | 2025 | Wegovy |
| Pharmacosmos Therapeutics INC. | $19.86 | 2022 | |
| Ucb, INC. | $19.78 | 2019 | |
| Sandoz INC. | $18.36 | 2024 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $15.73 | 2021 | |
| Alfasigma USA, INC. | $14.56 | 2020 | |
| Endogastric Solutions, INC | $14.12 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mastri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.